RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024. Monday, November 11th @ 4:30 p.m. ET Domestic:1-877-407-9127Internation ...

I covered Mineralys (NASDAQ: MLYS ) in April last year. It had a few things going that got me interested: It was a new IPO, had just published positive phase 2 data, and it had a strong board of directors. The stock took a deep About the TPT service Thanks for reading. At the Total Pharma Tracker, we offer the following :- ing Balance (millior Projected American Shared Revenue Backlog $250 $213 $200 $150 $106 $104 $101 $100 $50 $0 12/31/21 12/31/22 12/31/23 5/10/24 (projected*) Ending Balance Date *This cha ...

LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ: MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Mineralys released its second quarter 2024 financial results ...

"I am honored to join the Mineralys Board of Directors," stated Dr. Gold. "I look forward to working with the Company's executive team and fellow Board members to advance the treatment of cardiorenal metabolic disorders. There is significant potential with lorundrostat in offering a targeted treatment approach for hypertension and other diseases driven by dysregulated aldosterone." "The Board and I would like to express our collective gratitude to Olivier for his contributions and dedication to the Board. W ...

"We are delighted to welcome Alex to our Board of Directors as we advance the late-stage clinical development of lorundrostat for the treatment of hypertension and related cardiorenal metabolic disorders," stated Jon Congleton, Chief Executive Officer of Mineralys. "As a cardiologist and accomplished biopharmaceutical clinical development executive, Alex brings tremendous experience driving value for biopharmaceutical companies. We believe Alex's track record of successful pipeline development, regulatory a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-41614 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1966887 (Sta ...

Exhibit 99.1 Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • Pivotal Advance-HTN Trial – The ongoing Advance-HTN trial is evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to a standardized background treatment of two or three antihypertensive medications. • Pivotal Launch-HTN Phase 3 Trial – The Company's second ongoing pivotal trial of ...

Minji Kim, PhD. Chief Business Officer 20+ years of experience: Affamed, Jounce, Curis, Hoffman-LaRoche, Genentech Cindy Berejikian Balance sheet supports activities to execute on upcoming milestones | --- | --- | --- | |------------------------------------------------------------------|-------|-------| | | | | | | | | | Targeting Aldosterone in the Treatment of Cardiorenal Diseases | | | | Mar ch 2024 | | | We caution you that this presentation contains forward-looking statements. All statements other than ...

Mineralys Therapeutics, Inc. (OTCQX:HCHDF) Q4 2023 Earnings Conference Call March 21, 2024 8:30 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer and Chief Business Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Mary Kate - Bank of America Seamus Fernandez - Guggenheim Securities Operator Welcome to the Mineralys Therapeutics Fourth Quarter and Full Year 2023 Con ...

Exhibit 99.1 Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update – Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 – – Explore-CKD Phase 2 trial, a study for lorundrostat in hypertensive patients with stage 2-3b CKD on track for Q4 2024 to Q1 2025 topline data – – Conference call today at 8:30 a.m. ET – • ...